期刊文献+

减重代谢手术对肥胖患者心衰影响的系统评价和Meta分析 被引量:2

A Systematic Review and Meta-Analysis of Weight Loss Metabolic Surgery on Heart Failure in Obese Patients
下载PDF
导出
摘要 目的探讨减重代谢手术预防肥胖患者发生心衰的效果。方法计算机检索医学文献数据库相关文献,行质量评价并提取数据,采用Rev Man 5.3软件对数据进行Meta分析。结果共纳入13篇文献311170例患者。无心衰病史的肥胖患者减重代谢手术后心衰发生率低于对照组,差异有统计学意义[RR=0.35,95%CI(0.16,0.78),P=0.01];有心衰病史的肥胖患者在减重代谢手术后因心衰住院率低于对照组,差异无统计学意义[RR=0.76,95%CI(0.36,1.6),P=0.48];减重手术组心衰患者死亡率低于对照组,差异有统计学意义[RR=0.49,95%CI(0.41,0.58),P<0.00001]。结论减重代谢手术可预防肥胖患者心衰的发生,降低肥胖患者因心衰导致的死亡率,但需要高质量的前瞻性研究来验证。 Objective To investigate the effect of weight loss metabolic surgery in preventing heart failure for obese patients.Methods The relevant documents of medical literature database were retrieved by computer to perform quality evaluation and extract data.The Rev Man 5.3 software was used to merge extracted information with Meta.Results A total of 13 articles were included with 311170 patients.The incidence of heart failure in obese patients without a history of heart failure after weight loss metabolic surgery was lower than that of control group with statistically significant difference[RR=0.35,95%CI(0.16,0.78),P=0.01].The hospitalization rate of obese patients with a history of heart failure due to heart failure after weight loss metabolic surgery was lower than that of control group without statistically significant difference[RR=0.76,95%CI(0.36,1.6),P=0.48].The mortality rate of heart failure patients in weight loss metabolic surgery group was lower than that of control group with statistically significant difference[RR=0.49,95%CI(0.41,0.58),P<0.001].Conclusion Weight loss metabolic surgery could prevent heart failure occurrence in obese patients and reduce obese patients’mortality due to heart failure,but it is need to verify by high-quality prospective studies.
作者 王玲玲 张雪梅 廖婧 印义琼 Wang Lingling;Zhang Xuemei;Liao Jing(West China School of Nursing,Sichuan University,Chengdu,Sichuan 610041;Geriatrics Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041;Gatroenterology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China)
出处 《四川医学》 CAS 2020年第9期973-979,共7页 Sichuan Medical Journal
关键词 肥胖 心衰 减重代谢手术 META分析 obesity heart failure weight loss metabolic surgery meta-analysis
  • 相关文献

参考文献5

二级参考文献72

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2789

同被引文献25

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部